| The neuropathological diagnosis of Alzheimer's disease |
93 |
| Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles |
45 |
| New insights into the role of TREM2 in Alzheimer's disease |
45 |
| Advances in developing novel therapeutic strategies for Alzheimer's disease |
40 |
| Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease |
36 |
| Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid- pathology |
36 |
| Development and validation of a simplified method to generate human microglia from pluripotent stem cells |
35 |
| Inoculation of alpha-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve |
34 |
| The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease |
32 |
| Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-beta 42 by LRP1-dependent apolipoprotein E isoform-specific mechanism |
29 |
| Peripheral immune system in aging and Alzheimer's disease |
28 |
| Dementia with Lewy bodies: an update and outlook |
28 |
| Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer's disease |
28 |
| alpha-synuclein in the pathophysiology of Alzheimer's disease |
27 |
| 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling |
26 |
| Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease |
26 |
| Glial phagocytic clearance in Parkinson's disease |
26 |
| Endo-lysosomal dysregulations and late-onset Alzheimer's disease: impact of genetic risk factors |
25 |
| Dural lymphatics regulate clearance of extracellular tau from the CNS |
24 |
| Glucocerebrosidase and its relevance to Parkinson disease |
24 |
| Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease |
23 |
| The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans |
22 |
| Glucose transporter 1 critically controls microglial activation through facilitating glycolysis |
21 |
| Extracellular alpha-synuclein levels are regulated by neuronal activity |
19 |
| Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy |
19 |
| Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease |
19 |
| Reduced presynaptic vesicle stores mediate cellular and network plasticity defects in an early-stage mouse model of Alzheimer's disease |
17 |
| Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation |
17 |
| Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics |
17 |
| Apolipoprotein E inhibitory network dysfunction, and Alzheimer's disease |
17 |
| Deregulation of neuronal miRNAs induced by amyloid-beta or TAU pathology |
17 |
| Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury |
16 |
| Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration |
16 |
| Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2) |
16 |
| LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same |
16 |
| Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses |
16 |
| Impaired dopamine metabolism in Parkinson's disease pathogenesis |
16 |
| Microglia affect alpha-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease |
15 |
| Early lysosomal maturation deficits in microglia triggers enhanced lysosomal activity in other brain cells of progranulin knockout mice |
15 |
| Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation |
14 |
| Long-read sequencing across the C9orf72 'GGGGCC' repeat expansion: implications for clinical use and genetic discovery efforts in human disease |
14 |
| ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans |
13 |
| Protective paraspeckle hyper-assembly downstream of TDP-43 loss of function in amyotrophic lateral sclerosis |
13 |
| Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease |
13 |
| PU.1 regulates Alzheimer's disease-associated genes in primary human microglia |
13 |
| A new hypothesis for Parkinson's disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics |
13 |
| Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice |
12 |
| Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the hippocampus and cortex |
12 |
| Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer's disease-related proteins |
12 |
| Differences in neurotropism and neurotoxicity among retrograde viral tracers |
11 |
